Description: Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.
Home Page: www.organon.com
OGN Technical Analysis
30 Hudson Street
Jersey City,
NJ
07302
United States
Phone:
551 430 6000
Officers
| Name | Title |
|---|---|
| Mr. Kevin Ali | CEO & Director |
| Mr. Matthew M. Walsh | Exec. VP & CFO |
| Ms. Susanne Gabriele Fiedler | Exec. VP & Chief Commercial Officer |
| Dr. Sandra Milligan J.D., M.D. | Exec. VP and Head of R&D |
| Ms. Rachel A. Stahler | Exec. VP & Chief Information Officer |
| Ms. Jennifer Halchak | VP of Investor Relations |
| Mr. Kirke Weaver | Gen. Counsel & Corp. Sec. |
| Mr. Aaron Falcione | Exec. VP & Chief HR Officer |
| Mr. Joseph T. Morrissey Jr. | Exec. VP and Head of Manufacturing & Supply |
| Mr. Vittorio Nisita | Exec. VP & Head of Global Bus. Services |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 5.0302 |
|---|---|
| Trailing PE: | 7.6253 |
| Price-to-Book MRQ: | 1.8433 |
| Price-to-Sales TTM: | 1.1433 |
| IPO Date: | 2021-06-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 10000 |